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A confusional state associated with use of lanthanum
carbonate in a dialysis patient: a case report
Sir,
Muller and colleagues report a case of febrile confusion
and ‘diverticular flare-up’ with abdominal pain and specu-
late an association with lanthanum carbonate (LC) because
discontinuation of LC treatment and initiation of antibiotic
therapy led to recovery [1]. They support their argument
with the radiographic detection of lanthanum particles in
the gastrointestinal tract, a reduction of plasma lanthanum
levels following discontinuation of treatment and a selec-
tivereviewoftheliterature.However,thereisnoconvincing
argument for an association with LC treatment.
The only available presentation of LC (FOSRENOL
R 
,
Shire Pharmaceuticals, Basingstoke, UK) is a chewable
tablet containing no excipients to aid dispersal. Tablets
shouldbetakenwithorimmediatelyaftermealsandshould
be chewed completely; intact tablets should not be swal-
lowed [2]. The size of the lanthanum particles evident in
the radiograph is consistent with that of chewed LC, as
has been seen in other published reports and not been
associated with gastrointestinal obstruction [3,4]. As ex-
pected, and noted by the authors, the lanthanum particles
‘continued to migrate through the digestive tract’. In con-
trast, the case report by Kurtz (sic) et al. (Kongress der
Gesellschaft f¨ ur Nephrologie, Tubingen, Germany, 2008)
cited by Muller clearly showed the presence of un-chewed
tablets.
Speculation that deposition of lanthanum in the central
nervous system (CNS) resulted in the confusional state
draws on controversial evidence from in vivo studies [5,6].
Recent data from a study examining the potential for con-
tamination of tissue samples in dietary studies of LC leads
onetoquestionthevalidityofthisevidence[7].Inthisstudy
comparing dietary, oral gavage and intravenous administra-
tion, lanthanum was only detectable in brain tissue from
rats administered LC in their diet. It appears that despite
stringent efforts to limit contamination, lanthanum is still
transferred to tissue samples during autopsy [7]. In another
recent study, Bervoets et al. demonstrated no difference in
the brain concentrations of lanthanum between healthy rats
and those with chronic renal failure treated by oral gav-
age with LC for 20 weeks [8]. Levels remained around the
lower limit of quantification for the assay. The results of
these studies add to the weight of evidence in the litera-
ture that lanthanum does not cross the blood–brain barrier,
even in the uraemic inflammatory and other disease states
[8–10]. In the study by Feng et al., which suggests alter-
ation of CNS function with lanthanum treatment, changes
inbiochemicalparameterswerenotdosedependentandnot
predictive of effects in humans as discussed in the literature
[6,11].
In addition, the authors do not consider the clinical data
on the effects of LC on cognitive function [12]. Altmann
et al. found no difference in the rate of cognitive decline in
dialysis patients randomized to LC or standard phosphate-
binder therapy (mainly calcium based) [12]. In this study,
the median plasma lanthanum level of LC-treated patients
stabilized at ∼0.3 (range 0.0–3.1) ng/mL. Therefore, the
plasmalanthanumvalueof2.13µg/LnotedbyMulleretal.
is neither ‘higher than normal’ compared with a population
treated with LC for 2 years, nor is it associated with ex-
cessive cognitive decline. Extrapolation from in vivo tissue
deposition data [8] based on human plasma lanthanum lev-
els [13] is not scientifically sound and the conclusion that
toxic levels of lanthanum can be reached in patients with
renal failure is purely speculative, with no human or animal
evidence provided.
This patient was elderly and had diffuse cerebral atrophy
on CT scan. Her presenting symptoms included dizziness
with falling and confusion. Infection is commonly impli-
cated with the etiology of several conditions that cause
confusion in the elderly, and therapy of the underlying con-
dition leads to recovery [14]. Benzodiazepine use is alsoNephrol Dial Transplant (2009) 24: 3899 3899
commonly associated with confusion in the elderly. Either
of these factors areplausible explanations forthe confusion
experienced by this patient.
In summary, this patient with known diverticular disease
presentedwithafebrileepisodethatrespondedtoantibiotic
treatment. The authors noted the expected radio-opaque
appearance of lanthanum in the gastrointestinal tract and
plasma lanthanum levels within the range observed in piv-
otal clinical trials. Neither finding has been convincingly
linked to the patient’s presentation; therefore, there are no
grounds for revising the benefit–risk profile for LC.
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Reply
In response to Dr Smyth’s letter to the editor, we would
like to remind readers that lanthanum carbonate has indeed
shown its efficacy, but that many safety concerns remain
unsolved. We would like to draw attention to two main
points brought out in our case report:
1. Gastro-intestinal effects: Lanthanum has been shown to
induce a number of gastrointestinal effects [1].
Patients with acute peptic ulcer, ulcerative colitis, Crohn
disease or bowel obstruction were not included in the
pivotal FOSRENOL(R) study, its 6-year follow-up re-
port [2] or in Finn’s work [3]. Therefore, caution should
be exercised in patients with these conditions [4]. There
was more withdrawal in patients treated with lanthanum
mainly attributable to digestive disorders in these studies.
Our patient had previous digestive disorders and therefore
should be considered a high-risk patient for digestive side
effects.
In our patient, the plasmatic lanthanum level was
2.13 µg/l. In the public assessment report [5], the mean
concentration for long-term ingestion of 3 g lanthanum/day
ranges from 0.5 to 0.6 ng/ml. There was no significant dose
or time effect on treatment. Altman’s study reported the
same mean plasmatic value—0.3 ng/ml—but a wide range
(0.0–3.1 ng/ml). More information would be required to
explain this difference.
It has been shown that the tissue concentration is higher
thantheplasmaconcentrationsowecannotassumethatlan-
thanum is not nontoxic. Tissue accumulation is seen partic-
ularly in the gastro-intestinal tract, lymphoreticular system,
bone, liver and spleen [5]. Recently, Davis and Jerrold re-
ported the detection of lanthanum deposits in a mesenteric
lymph node in a patient 3 years after exposure [6].
The degree of digestive absorption has not been evalu-
ated, nor has the excretion of the unabsorbed dose of lan-
thanum in the faeces been demonstrated in humans [5,7].
ThetwoFDAreviewersformarketapprovaloflanthanum
(Drs Pelayo and Oluferni [1]) made a negative recommen-
dation because of the gastro-intestinal effects and the un-
known accumulation and elimination of the product, which
presented ‘a real risk of malnutrition and additional injury
in this population’. They stated that it can be ‘unacceptably
toxic’.Thesponsorwasinchargeofprovidingproofonthis
point but was unable to do so.
2. The effects on the central nervous system: a number of
animal studies indicate significant brain exposure [8].
The blood–brain barrier can be damaged when there is sig-
nificantinflammation,tumours,etc.andcanallowselective
deliveryofpharmacologicalagentstothebrain[9].Theim-
pactoflanthanideonbrainfunctionisnotinsignificant[10].
It is known that when it passes the blood–brain barrier in
animals, it can be toxic to the nervous system and cogni-
tion [11,12]. In healthy rats, Damment et al. [13] showed
that the lanthanum brain concentration found is considered
contamination.
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